Genzyme appoints David Meeker as new CEO
Genzyme, a subsidiary of Sanofi, has appointed David Meeker as the new Chief Executive Officer, with effect from 1 November.
Genzyme will incorporate the Rare Disease business and the Multiple Sclerosis franchise, under the leadership of the new CEO, the company said.
David joined Genzyme in 1994 as Medical Director to work on the Cystic Fibrosis Gene Therapy program.
He has been the president of the Global Rare Disease Business and looked into the global launches of Aldurazyme, Fabrazyme and Myozyme.
In 2009, David became the Chief Operating Officer of Genzyme.
Sanofi CEO Christopher A Viehbacher said David Meeker's combination of medical and business experience will drive Genzyme's range of products forward and help in the delivery of therapies.
Sanofi focuses on discovery, development and distribution of therapeutic solutions with special emphasis on diabetes solutions, human vaccines, innovative drugs, rare diseases and consumer healthcare.
Related Insight
Suppliers Directory
BioClinica - Global Clinical Trial Solutions. Real-World Results
Bio-Imaging Technologies and Phoenix Data Systems have joined forces to become BioClinica, delivering new value and a breakthrough in eClinical services like never before.
Drug Research > Drug Discovery & Development > Suppliers
C3 Research Associates - Clinical Research Development and Management Group
C3 Research Associates is a quality-focused clinical research development and management group supporting innovative biotechnology, medical device and pharmaceutical organizations, stewarding therapeutics from preclinical through phase IV drug development and successful market life cycle.
Drug Research > Drug Discovery & Development > Suppliers
Lomapharm - Your Competent Partner for Solid and Liquid Pharmaceuticals
Lomapharm®: Pharmaceutical competence with a long tradition.
Drug Research > Drug Discovery & Development > Suppliers
Deallus Group – Strategy Consulting for Life Sciences
Deallus supports strategy development and decision making in life-science organisations around the world. We provide objective guidance which can be used with confidence at brand, franchise and corporate management levels within your business.
Drug Research > Drug Discovery & Development > Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Discovery & Development Intelligence
CaseBase Management
Published by BaseCon
Drug Research > Drug Discovery & Development > White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.